TY - JOUR
T1 - Impact of Bronchiectasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History
AU - for the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) investigators
AU - Izquierdo, Manuel
AU - Marion, Chad R.
AU - Genese, Frank
AU - Newell, John D.
AU - O’Neal, Wanda K.
AU - Li, Xingnan
AU - Hawkins, Gregory A.
AU - Barjaktarevic, Igor
AU - Barr, R. Graham
AU - Christenson, Stephanie
AU - Cooper, Christopher B.
AU - Couper, David
AU - Curtis, Jeffrey
AU - Han, Meilan K.
AU - Hansel, Nadia N.
AU - Kanner, Richard E.
AU - Martinez, Fernando J.
AU - Paine, Robert
AU - Tejwani, Vickram
AU - Woodruff, Prescott G.
AU - Zein, Joe G.
AU - Hoffman, Eric A.
AU - Peters, Stephen P.
AU - Meyers, Deborah A.
AU - Bleecker, Eugene R.
AU - Ortega, Victor E.
AU - Alexis, Neil E.
AU - Anderson, Wayne H.
AU - Arjomandi, Mehrdad
AU - Barjaktarevic, Igor
AU - Barr, R. Graham
AU - Basta, Patricia
AU - Bateman, Lori A.
AU - Bhatt, Surya P.
AU - Boucher, Richard C.
AU - Bowler, Russell P.
AU - Christenson, Stephanie A.
AU - Comellas, Alejandro P.
AU - Cooper, Christopher B.
AU - Couper, David J.
AU - Criner, Gerard J.
AU - Crystal, Ronald G.
AU - Curtis, Jeffrey L.
AU - Doerschuk, Claire M.
AU - Dransfield, Mark T.
AU - Drummond, Brad
AU - Freeman, Christine M.
AU - Galban, Craig
AU - Han, Mei Lan K.
AU - Martinez, Fernando J.
N1 - Publisher Copyright:
© 2023 COPD Foundation. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Rationale: Bronchiectasis is common among those with heavy smoking histories, but risk factors for bronchiectasis, including alpha-1 antitrypsin deficiency, and its implications for COPD severity are uncharacterized in such individuals. Objectives: To characterize the impact of bronchiectasis on COPD and explore alpha-1antitrypsin as a risk factor for bronchiectasis. Methods: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) participants (N=914; ages 40–80 years; ≥20-pack-year smoking) had high-resolution computed tomography (CT) scans interpreted visually for bronchiectasis, based on airway dilation without fibrosis or cicatrization. We performed regression-based models of bronchiectasis with clinical outcomes and quantitative CT measures. We deeply sequenced the gene encoding -alpha-1 antitrypsin, SERPINA1, in 835 participants to test for rare variants, focusing on the PiZ genotype (Glu366Lys, rs28929474). Measurements and Main Results: We identified bronchiectasis in 365 (40%) participants, more frequently in women (45% versus 36%, p=0.0045), older participants (mean age=66[standard deviation (SD)=8.3] versus 64[SD=9.1] years, p=0.0083), and those with lower lung function (forced expiratory volume in 1 second [FEV1] percentage predicted=66%[SD=27] versus 77%[SD=25], p<0.0001; FEV1 to forced vital capacity [FVC] ratio=0.54[0.17] versus 0.63[SD=0.16], p<0.0001). Participants with bronchiectasis had greater emphysema (%voxels ≤-950 Hounsfield units, 11%[SD=12] versus 6.3%[SD=9], p<0.0001) and parametric response mapping functional small airways disease (26[SD=15] versus 19[SD=15], p<0.0001). Bronchiectasis was more frequent in the combined PiZZ and PiMZ genotype groups compared to those without PiZ, PiS, or other rare pathogenic variants (N=21 of 40 [52%] versus N=283 of 707[40%], odds ratio [OR]=1.97; 95% confidence interval [CI]=1.002, 3.90, p=0.049), an association attributed to White individuals (OR=1.98; 95%CI = 0.9956, 3.9; p=0.051). Conclusions: Bronchiectasis was common in those with heavy smoking histories and was associated with detrimental clinical and radiographic outcomes. Our findings support alpha-1antitrypsin guideline recommendations to screen for alpha-1 antitrypsin deficiency in an appropriate bronchiectasis subgroup with a significant smoking history.
AB - Rationale: Bronchiectasis is common among those with heavy smoking histories, but risk factors for bronchiectasis, including alpha-1 antitrypsin deficiency, and its implications for COPD severity are uncharacterized in such individuals. Objectives: To characterize the impact of bronchiectasis on COPD and explore alpha-1antitrypsin as a risk factor for bronchiectasis. Methods: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) participants (N=914; ages 40–80 years; ≥20-pack-year smoking) had high-resolution computed tomography (CT) scans interpreted visually for bronchiectasis, based on airway dilation without fibrosis or cicatrization. We performed regression-based models of bronchiectasis with clinical outcomes and quantitative CT measures. We deeply sequenced the gene encoding -alpha-1 antitrypsin, SERPINA1, in 835 participants to test for rare variants, focusing on the PiZ genotype (Glu366Lys, rs28929474). Measurements and Main Results: We identified bronchiectasis in 365 (40%) participants, more frequently in women (45% versus 36%, p=0.0045), older participants (mean age=66[standard deviation (SD)=8.3] versus 64[SD=9.1] years, p=0.0083), and those with lower lung function (forced expiratory volume in 1 second [FEV1] percentage predicted=66%[SD=27] versus 77%[SD=25], p<0.0001; FEV1 to forced vital capacity [FVC] ratio=0.54[0.17] versus 0.63[SD=0.16], p<0.0001). Participants with bronchiectasis had greater emphysema (%voxels ≤-950 Hounsfield units, 11%[SD=12] versus 6.3%[SD=9], p<0.0001) and parametric response mapping functional small airways disease (26[SD=15] versus 19[SD=15], p<0.0001). Bronchiectasis was more frequent in the combined PiZZ and PiMZ genotype groups compared to those without PiZ, PiS, or other rare pathogenic variants (N=21 of 40 [52%] versus N=283 of 707[40%], odds ratio [OR]=1.97; 95% confidence interval [CI]=1.002, 3.90, p=0.049), an association attributed to White individuals (OR=1.98; 95%CI = 0.9956, 3.9; p=0.051). Conclusions: Bronchiectasis was common in those with heavy smoking histories and was associated with detrimental clinical and radiographic outcomes. Our findings support alpha-1antitrypsin guideline recommendations to screen for alpha-1 antitrypsin deficiency in an appropriate bronchiectasis subgroup with a significant smoking history.
KW - COPD
KW - alpha-1 antitrypsin
KW - bronchiectasis
KW - lung function
UR - http://www.scopus.com/inward/record.url?scp=85168959045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168959045&partnerID=8YFLogxK
U2 - 10.15326/jcopdf.2023.0388
DO - 10.15326/jcopdf.2023.0388
M3 - Article
AN - SCOPUS:85168959045
SN - 2372-952X
VL - 10
SP - 199
EP - 210
JO - Chronic Obstructive Pulmonary Diseases
JF - Chronic Obstructive Pulmonary Diseases
IS - 3
ER -